NIH Consensus Development Conference summary: thrombolytic therapy in thrombosis.
D003365:Costs and Cost Analysis; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009316:National Institutes of Health (U.S.); D011655:Pulmonary Embolism / Q000188:drug therapy*; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy*; D014481:United States; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator